Laurus Labs 
#Lauruslabs 

#Q3FY25

Recorded Good numbers this quarter & management believes Q4 is also on the same line to outperform, but this sudden global news made some impact on the stock. 

Here's what management says : 
- PEPFAR funding is about 20% of total ARV programs ongoing at global level.

- Likewise, Laurus has about 20% of ARV sales from PEPFAR.

- The ARV sales for Laurus is about INR 24b forming 46% of sales. PEPFAR-related ARV business would be ~INR 5b, forming 9% of consolidated sales.

ARV business is relatively less profitable business compared to other segments of Laurus & hence the maximum impact on EBITDA could be of 4-5% of FY26 EBITDA even if it converts to closure of funding.

Technical side : 

- Overreaction from market on the news with earnings reaction amplifying the fall. As of now on a larger structure nothing looks bad. The stock was supposed to fall lets say 5% but due to bad market the fall went up till 12-13%.

- For traders further wait is needed until a fresh upmove, while investors who believe the long story is intact can decide here in here. 

#Investment